Research programme: peptide based therapeutics - KAEL-GemVax
Latest Information Update: 07 Dec 2023
At a glance
- Originator KAEL-GemVax
- Class Anti-inflammatories; Peptides; Urologics
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain disorders; Genitourinary disorders; Inflammation; Unspecified
Most Recent Events
- 27 Nov 2023 Early research in Brain disorders in South Korea (unspecified route), prior to November 2023 (KAEL-GemVax pipeline, November 2023)
- 27 Nov 2023 Early research in Genitourinary disorders in South Korea (unspecified route), prior to November 2023 (KAEL-GemVax pipeline, November 2023)
- 27 Nov 2023 Early research in Inflammation in South Korea (unspecified route), prior to November 2023 (KAEL-GemVax pipeline, November 2023)